Ibutilide fumarate

Drugs of the Future

Volumn 21, Issue 9, 1996, Pages 894-900

  Robinson, Casey ^a   Robinson, Ken ^a   Castaner J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ANTIARRHYTHMIC AGENT; DOFETILIDE; IBUTILIDE; IBUTILIDE FUMARATE; POTASSIUM CHANNEL; SEMATILIDE; SOTALOL; UNCLASSIFIED DRUG;

DRUG CLASSIFICATION; DRUG SAFETY; DRUG SYNTHESIS; ELECTROCARDIOGRAM; ENANTIOMER; GUINEA PIG; HEART; HEART ARRHYTHMIA; HEART MUSCLE; HEART VENTRICLE; HUMAN; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PATCH CLAMP; RABBIT; SHORT SURVEY; TACHYCARDIA;

EID: 0029801174     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.09.373165     Document Type: Short Survey

References (54)

1. Hester, J.B., Gibson, J.K., Cimini, M.G., Emmert, D.E., Locker, P.K., Perricone, S.C., Skaletzky, L.L., Sykes, J.K., West, B.E. N-[(σ-Amino-1-hydroxyalkyl)phenyl]methanesulfonamide derivatives with Class III antiarrhythmic activity. J Med Chem 1991, 34: 308-15.
2. Hester, J.B. Jr. (The Upjohn Co.). N-(Aminoalkylphenyl)sulfonamides their preparation and therapeutic use. EP 164865, JP 85239458, US 5155268.
3. Stolle, W.T., Stelzer, L.S., Hester, J.B., Perricone, S.C., Hsi, R.S.P. Synthesis of radiolabeled racemic and enantiomeric antiarrhythmic agents. J Label Compound Radiopharm 1994, 34: 929.
4. Smith, E.R. Pathophysiology of cardiac electrical disturbances. In: Physiopathology of the Cardiovascular System, J.S. Alpert (Ed.), Little Brown & Company, Boston/Toronto, 1984, 239-65.
5. Cimini, M.G., Brunden, M.N., Gibson, J.K. Effects of ibutilide fumarate, a novel antiarrhythmic agent, and its enantiomers on isolated rabbit myocardium. Eur J Pharmacol 1992, 222: 93-8.
6. Vaughan Williams, E.M. Classification of antiarrhythmic drugs. In: Symposium on Cardiac Arrhythmias, E. Sandoe, E. Flensted-Jensen, K.H. Olsen (Eds.), Astra, Södertälje, 1970, 449-69.
7. Vaughan Williams, E.M. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984, 24: 129-47.
8. CAST investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infaction. New Engl J Med 1989, 321: 406-12.
9. Colatsky, T.J. Mechanisms of action of lidocaine and quinidine on action potential duration in rabbit cardiac Purkinje fibers - An effect on steady state sodium current? Circ Res 1982, 50: 17-27.
10. Burkart, F., Pfisterer, M., Kiowski, W., Follath, F., Burckhardt, D., Jordi, H. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel antiarrhythmic study of infarct survival (BASIS). J Amer Coll Cardiol 1990, 16: 1711-8.
11. Wit, A.L. Cardiac arrhythmias: Electrophysiologic mechanisms. In: Mechanisms and Treatment of Cardiac Arrhythmias; Relevance of Basic Studies to Clinical Management, H.J. Reiser, L.N. Horowitz (Eds.), Urban and Schwarzenberg, Baltimore, 1985, 11-37.
12. Surawicz, B. Ventricular arrhythmias: Why is it so difficult to find a pharmacologic cure? J Amer Coll Cardiol 1989, 14: 1401.
13. Heissenbuttel, R.H., Bigger, J.T. Bretylium tosylate: A newly available antiarrhythmic drug for ventricular arrhythmias. Ann Intern Med 1979, 91: 229-38.
14. Kaski, J.C., Girotti, L.A., Elizari, M.V. Efficacy of amiodarone during long term treatment of potentially dangerous ventricular arrhythmias in patients with chronic stable ischaemic heart disease. Amer Heart J 1984, 107: 648-91.
15. Schwartz, J., Cracker, K., Wynn, J., Simberg, J.C. The antiarrhythmic effects of d-sotalol. Amer Heart J 1987, 114: 539-44.
16. Carmeleit, E. Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. J Pharmacol Exp Ther 1984, 232: 817-25.
17. Steinberg, M.I., Michelson, E.L Cardiac electrophysiologic effects of specific Class III substances. In: Mechanism and Treatment of Cardiac Arrhythmias; Relevenace of Basic Studies to Clinical Management, H.J. Reiser, L.N. Horowitz (Eds.), Urban and Schwarzenberg, Baltimore, 1985, 263-81.
18. K activation. Circulation 1987, 76(Suppl. 4): Abst 0594.
19. Arena, J.P., Kass, R.S. Block of heart potassium channels by clofilium and its tertiary analogs: Relationship between drug structure and type of channel blocked. Mol Pharmacol 1988, 34: 606-66.
20. Colatsky, T.J., Follmer, C.H., Starmer, C.F. Channel specificity in antiarrhythmic drug action: Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 1990, 82: 2235-42.
21. + current: Differential sensitivity to block by Class III antiarrhythmic agents. J Gen Physiol 1990, 96: 195-215.
22. Baiser, J.R., Hondeghem, L.M., Roden, D.M. Suppression of time-dependent outward current in guinea pig ventricular myocytes. Action of quinidine and amiodarone. Circ Res 1991, 69: 519-29.
23. Gwilt, M., Arrowsmith, J.E., Blackburn, K.J., Burges, R.A., Cross, P.E., Dalrymple, H.W., Higgins, A.J. UK-68798: A novel, potent and highly selective Class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther 1991, 256: 318-24.
24. Roden, D.M. Current status of Class III antiarrhythmic therapy. Amer J Cardiol 1993, 72: 44B-9B.
25. Singh, B.N. Arrhythmia control by prolonging repolarization: The concept and its potential therapeutic impact. Eur Heart J 1993, 14(Suppl. H): 14-23.
26. Harris, L., McKenna, W.J., Rowland, E., Holt, D.W., Storey, G.C.A., Krikler, D.M. Side effects of long term amiodarone therapy. Circulation 1983, 67: 45-51.
27. + current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992, 262: 99-108.
28. Lee, K.S., Tsai, T.D., Lee, E.W. Membrane activity of Class III antiarrhythmic compounds: A comparison between ibutilide, d-sotalol, E-4031, sematilide and dofetilide. Eur J Pharmacol 1993, 234: 43-53.
29. Ellenbogen, K.A., Wood, M.A., Stambler, B.S., Wakefield, L.K., VanderLugt, J.T. Conversion of atrial fibrillation and flutter by intravenous ibutilide: A multicenter dose response study. J Amer Coll Cardiol 1994, 23: 227A.
30. Jungbluth, G.L., VanderLugt, J.T., Kabell, G., Walters, R.R. The pharmacokinetics (PK) and pharmacodynamics (PD) of ibutilide fumarate (IBUT) after intravenous infusion in healthy volunteers. Pharm Res 1990, 7(Suppl. 9): S211.
31. Corvert, band of ibutilide fumarate injection, The Upjohn Company, package insert, January 1996.
32. Kr in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. Circulation 1995, 91: 1799-806.
33. Lee, K.S., Gibson, J.K. Unique ionic mechanism of action of ibutilide on freshly isolated heart cells (letter). Circulation 1995, 92: 2755-7.
34. Jungbluth, G.L., Della-Coletta, A.A., VanderLugt, J.T. Evaluation of the pharmacokinetics and pharmacodynamics of ibutilide fumarate and its enantiomers in healthy male volunteers. Pharm Res 1991, 8(Suppl. 10): S249.
35. Buchanan, L.V., Kabell, G., Turcotte, U.M., Brunden, M.N., Gibson, J.K. Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: A comparative study with sotalol and encainide. J Cardiovasc Pharmacol 1992, 19: 256-63.
36. Buchanan, L.V., Turcotte, U.M., Kabell, G., Gibson, J.K. Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter. J Cardiovasc Pharmacol 1993, 22: 10-4.
37. Nabih, M.A., Prcevski, P., Fromm, B.S., Lavine, S.J., Elnabtity, M., Munir, A., Steinman, R.T., Meissner, M.D., Lehmann, M.H. Effect of ibutilide, a new Class III agent, on sustained atrial fibrillation in a canine model of acute ischemia and myocardial dysfunction induced by microembolization. Pacing Clin Electrophysiol 1993, 16: 1975-83.
38. Wesley, R.C. Jr., Farkhani, F., Morgan, D., Zimmerman, D. Ibutilide: Enhanced defibrillation via plateau sodium current activation. Amer J Physiol 1993, 264: H1269-74.
39. Labhasetwar, V., Underwood, T., Heil, R.W. Jr., Gallagher, M., Langberg, J., Levy, R.J. Epicardial administration of ibutilide from polyurethane matrices: Effects on defibrillation threshold and electrophysiologic parameters. J Cardiovasc Pharmacol 1994, 24: 826-40.
40. Buchanan, L.V., Kabell, G., Gibson, J.K. Acute intravenous conversion of canine atrial flutter: Comparison of antiarrhythmic agents. J Cardiovasc Pharmacol 1995, 25: 539-44.
41. Tweedie, D., Henderson, C., Kane, K. Glibenclamide, but not Class III drugs, prevents ischaemic shortening of the refractory period in guinea-pig hearts. Eur J Pharmacol 1993, 240: 251-7.
42. Kr, and effects on myocardial refractoriness for Class III antiarrhythmic agents. J Cardiovasc Pharmacol 1995, 25: 336-40.
43. Buchanan, L.V., Kabell, G., Brunden, M.N., Gibson, J.K. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 1993, 22: 540-9.
44. Friedrichs, G.S., Chi, L., Black, S.C., Manley, P.J., Oh, J.Y., Lucchesi, B.R. Antifibrillatory effects of ibutilide in the rabbit isolated heart: Mediation via ATP-dependent potassium channels. J Pharmacol Exp Ther 1993, 266: 1348-54.
45. Lee, K.S., Tsien, R.W. High selectivity of calcium channels in single dialyzed heart cells of the guinea-pig. J Physiol (Lond) 1984, 354: 253-72.
46. Lee, K.S., Akaike, N., Brown, A.M. The suction pipette method for internal perfusion and voltage camp of small excitable cells. J Neurosci Meth 1980, 2: 51-78.
47. DiMarco, J.P. Cardioversion of atrial flutter by intravenous ibutilide, a new Class III antiarrhythmic agent. J Amer Coll Cardiol 1991, 17(2, Suppl. A): 324A.
48. VanderLugt, J.T., Gaylor, S.K., Wakefield, L.K., Jungbluth, G.L., Walters, R.R., Kabell, G.G. Effects of ibutilide fumarate, a new Class III antiarrhythmic agent, in man. Clin Pharmacol Ther 1991, 49: 188.
49. Stambler, B.S., Wood, M.A., Belz, M.K., Sperry, R.E., VanderLugt, J.T., Ellenbogen, K.A. Electrophysiologic determinants of pharmacologic conversion of human atrial fibrillation and flutter: Enhanced efficacy of ibutilide a new Class III antiarrhythmic drug. Circulation 1993, 88(4, Part 2): Abst 2396.
50. Guo, G.B.F., Ellenbogen, K.A., Wood, M.A. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. Circulation 1994, 90(4, Part 2): Abst 2014.
51. Stambler, B.S., Portnow, A.S., Wood, M.A. et al. Proven efficacy of repeated dose intravenous ibutilide, a Class III antiarrhythmic drug, for rapid termination of chronic atrial flutter or fibrillation: Results of a multicenter placebo-controlled study. J Amer Coll Cardiol 1995, Feb(special issue): 230A.
52. Ellenbogen, K.A., Stambler, B.S., Wood, M.A., Sager, P.T., Wesley, R.C. Jr., Meissner, M.D., Zoble, R.G., Wakefield, L.K., Perry, K.T., VanderLugt, J.T. Efficacy of intravenous ibutilide for acute termination of atrial fibrillation and atrial flutter: A dose response study. J Amer Coll Cardiol 1996, 28: 130-6.
53. Jungbluth, G.L., VanderLugt, J.T., Welshman, I.R., Dietz, A.J. Relationship between subject age and QTc interval prolongation induced by the Class III antiarrhythmic drug ibutilide. Clin Pharmacol Ther 1996, 59: Abst P11-21.
54. New product intros. Drug News Perspect 1996, 9(3): 164.